Medtronic PLC $MDT Shares Bought by Hedeker Wealth LLC

Hedeker Wealth LLC boosted its holdings in shares of Medtronic PLC (NYSE:MDT) by 1.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,261 shares of the medical technology company’s stock after purchasing an additional 654 shares during the period. Hedeker Wealth LLC’s holdings in Medtronic were worth $4,033,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in shares of Medtronic during the 1st quarter valued at $26,000. Twin Tree Management LP acquired a new stake in shares of Medtronic during the first quarter worth $29,000. Activest Wealth Management raised its position in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after purchasing an additional 322 shares during the period. Investment Management Corp VA ADV lifted its holdings in shares of Medtronic by 144.2% during the first quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 238 shares during the last quarter. Finally, GFG Capital LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at $36,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE:MDT opened at $95.92 on Friday. The firm has a market cap of $123.04 billion, a price-to-earnings ratio of 26.42, a P/E/G ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The business has a fifty day simple moving average of $94.43 and a 200 day simple moving average of $90.39.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion for the quarter, compared to the consensus estimate of $8.37 billion. During the same quarter in the previous year, the company posted $1.23 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. As a group, sell-side analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have issued reports on MDT shares. Wall Street Zen downgraded Medtronic from a “buy” rating to a “hold” rating in a report on Sunday, November 2nd. Robert W. Baird lifted their target price on shares of Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 20th. Royal Bank Of Canada restated an “outperform” rating and issued a $111.00 price target on shares of Medtronic in a research report on Friday, October 10th. Citigroup raised their price objective on shares of Medtronic from $101.00 to $112.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Finally, Truist Financial boosted their target price on shares of Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $103.06.

Insider Buying and Selling

In other Medtronic news, Director William R. Jellison purchased 2,500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $92.37 per share, for a total transaction of $230,925.00. Following the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares in the company, valued at $3,261,621.70. This represents a 19.46% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.26% of the company’s stock.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.